Estrogen receptor alpha expression in podocytes mediates protection against apoptosis in-vitro and in-vivo

PLoS ONE

Volumn 6, Issue 11, 2011, Pages

  Kummer, Sebastian ^a   Jeruschke, Stefanie ^a,b   van Wegerich, Laraessa ^a   Peters, Andrea ^a   Lehmann, Petra ^c   Seibt, Annette ^a   Mueller, Friederike ^d   Koleganova, Nadezda ^c   Halbenz, Elisabeth ^d   Schmitt, Claus Peter ^c   Bettendorf, Markus ^c   Mayatepek, Ertan ^a   Gross Weissmann, Marie Luise ^c   Oh, Jun ^a,d  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

^c UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANNEXIN; COLLAGEN TYPE 4; CYTOPLASM PROTEIN; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; FLUORESCEIN ISOTHIOCYANATE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; NUCLEAR PROTEIN; PUROMYCIN AMINONUCLEOSIDE; TETRAMETHYLRHODAMINE METHYL ESTER; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL CELL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL COUNT; CELL FUNCTION; CELL PROTECTION; CELL VIABILITY; CELL VOLUME; CONTROLLED STUDY; CYTOCHEMISTRY; ENZYME PHOSPHORYLATION; FEMALE; FLOW CYTOMETRY; GLOMERULOPATHY; GLOMERULUS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; KNOCKOUT MOUSE; MALE; MEMBRANE DEPOLARIZATION; MITOCHONDRIAL MEMBRANE POTENTIAL; MORPHOMETRICS; NONHUMAN; PODOCYTE; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; WILD TYPE; ANIMAL; CELL CULTURE; CYTOLOGY; DRUG EFFECT; GENETICS; METABOLISM; MOUSE; MOUSE MUTANT; PHYSIOLOGY;

MURINAE; MUS;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELLS, CULTURED; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY GLOMERULUS; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICE; MICE, KNOCKOUT; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PODOCYTES; PUROMYCIN AMINONUCLEOSIDE; SIGNAL TRANSDUCTION;

EID: 80855145543     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0027457     Document Type: Article

References (49)

1. Silbiger SR, Neugarten J, (1995) The impact of gender on the progression of chronic renal disease. Am J Kidney Dis 25: 515-533.
2. Neugarten J, Acharya A, Silbiger SR, (2000) Effect of gender on the progression of nondiabetic renal disease: a meta-analysis. J Am Soc Nephrol 11: 319-329.
3. Cattran DC, Reich HN, Beanlands HJ, Miller JA, Scholey JW, et al. (2008) The impact of sex in primary glomerulonephritis. Nephrol Dial Transplant 23: 2247-2253.
4. Kummer S, von Gersdorff G, Kemper MJ, Oh J, (2011) The influence of gender and sexual hormones on incidence and outcome of chronic kidney disease. Pediatric nephrology.
5. Berg UB, (2006) Differences in decline in GFR with age between males and females. Reference data on clearances of inulin and PAH in potential kidney donors. Nephrol Dial Transplant 21: 2577-2582.
6. Silbiger SR, Neugarten J, (2003) The role of gender in the progression of renal disease. Adv Ren Replace Ther 10: 3-14.
7. Elema JD, Arends A, (1975) Focal and segmental glomerular hyalinosis and sclerosis in the rat. Lab Invest 33: 554-561.
8. Hajdu A, Rona G, (1971) The protective effect of estrogens against spontaneous pancratic islet and renal changes in aging male rats. Experientia 27: 956-957.
9. Gilboa N, Magro AM, Han Y, Rudofsky UH, (1987) Contrasting effects of early and late orchiectomy on hypertension and renal disease in fawn-hooded rats. Life Sci 41: 1629-1634.
10. Elliot SJ, Berho M, Korach K, Doublier S, Lupia E, et al. (2007) Gender-specific effects of endogenous testosterone: female alpha-estrogen receptor-deficient C57Bl/6J mice develop glomerulosclerosis. Kidney Int 72: 464-472.
11. Doublier S, Lupia E, Catanuto P, Periera-Simon S, Xia X, et al. (2011) Testosterone and 17beta-estradiol have opposite effects on podocyte apoptosis that precedes glomerulosclerosis in female estrogen receptor knockout mice. Kidney Int 79: 404-413.
12. Sun J, Langer WJ, Devish K, Lane PH, (2006) Compensatory kidney growth in estrogen receptor-alpha null mice. AmJPhysiol Renal Physiol 290: F319-F323.
13. Gross ML, Adamczak M, Rabe T, Harbi NA, Krtil J, et al. (2004) Beneficial Effects of Estrogens on Indices of Renal Damage in Uninephrectomized SHRsp Rats. J Am Soc Nephrol 15: 348-358.
14. Tofovic SP, Dubey R, Salah EM, Jackson EK, (2002) 2-Hydroxyestradiol attenuates renal disease in chronic puromycin aminonucleoside nephropathy. J Am Soc Nephrol 13: 2737-2747.
15. Mundel P, Shankland SJ, (2002) Podocyte biology and response to injury. J Am Soc Nephrol 13: 3005-3015.
16. Kriz W, Gretz N, Lemley KV, (1998) Progression of glomerular diseases: is the podocyte the culprit? Kidney Int 54: 687-697.
17. Shankland SJ, (2006) The podocyte's response to injury: role in proteinuria and glomerulosclerosis. Kidney Int 69: 2131-2147.
18. Boland R, Vasconsuelo A, Milanesi L, Ronda AC, de Boland AR, (2008) 17beta-Estradiol signaling in skeletal muscle cells and its relationship to apoptosis. Steroids 73: 859-863.
19. Klinge CM, (2008) Estrogenic control of mitochondrial function and biogenesis. J Cell Biochem 105: 1342-1351.
20. Bjornstrom L, Sjoberg M, (2005) Mechanisms of estrogen receptor signaling: convergence of genomic and nongenomic actions on target genes. Mol Endocrinol 19: 833-842.
21. Koh PO, (2007) Estradiol prevents the injury-induced decrease of 90 ribosomal S6 kinase (p90RSK) and Bad phosphorylation. Neurosci Lett 412: 68-72.
22. Pearson G, Robinson F, Beers Gibson T, Xu BE, Karandikar M, et al. (2001) Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev 22: 153-183.
23. Song RX, Barnes CJ, Zhang Z, Bao Y, Kumar R, et al. (2004) The role of Shc and insulin-like growth factor 1 receptor in mediating the translocation of estrogen receptor alpha to the plasma membrane. Proceedings of the National Academy of Sciences of the United States of America 101: 2076-2081.
24. Thomas D, Patterson SD, Bradshaw RA, (1995) Src homologous and collagen (Shc) protein binds to F-actin and translocates to the cytoskeleton upon nerve growth factor stimulation in PC12 cells. The Journal of biological chemistry 270: 28924-28931.
25. Zhang Z, Kumar R, Santen RJ, Song RX, (2004) The role of adapter protein Shc in estrogen non-genomic action. Steroids 69: 523-529.
26. Inokuchi S, Shirato I, Kobayashi N, Koide H, Tomino Y, et al. (1996) Re-evaluation of foot process effacement in acute puromycin aminonucleoside nephrosis. Kidney Int 50: 1278-1287.
27. Ly JD, Grubb DR, Lawen A, (2003) The mitochondrial membrane potential (deltapsi(m)) in apoptosis; an update. Apoptosis 8: 115-128.
28. Arnold S, Beyer C, (2009) Neuroprotection by estrogen in the brain: the mitochondrial compartment as presumed therapeutic target. J Neurochem 110: 1-11.
29. Xia Z, Dickens M, Raingeaud J, Davis RJ, Greenberg ME, (1995) Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 270: 1326-1331.
30. Schiffer M, Bitzer M, Roberts IS, Kopp JB, ten Dijke P, et al. (2001) Apoptosis in podocytes induced by TGF-beta and Smad7. J Clin Invest 108: 807-816.
31. Birch Nielsen C, Krag S, R OS, Flyvbjerg A, Nyengaard J, et al. (2004) Transforming growth factor beta1-induced glomerulopathy is prevented by 17beta-estradiol supplementation. Virchows Arch 444: 561-566.
32. Lovegrove AS, Sun J, Gould KA, Lubahn DB, Korach KS, et al. (2004) Estrogen receptor alpha-mediated events promote sex-specific diabetic glomerular hypertrophy. Am J Physiol Renal Physiol 287: F586-591.
33. Couse JF, Yates MM, Walker VR, Korach KS, (2003) Characterization of the hypothalamic-pituitary-gonadal axis in estrogen receptor (ER) Null mice reveals hypergonadism and endocrine sex reversal in females lacking ERalpha but not ERbeta. Mol Endocrinol 17: 1039-1053.
34. Pare G, Krust A, Karas RH, Dupont S, Aronovitz M, et al. (2002) Estrogen receptor-alpha mediates the protective effects of estrogen against vascular injury. Circ Res 90: 1087-1092.
35. Nitsch W, Thein K, (1955) [Therapy of the nephrotic syndrome with estradiol.]. Ther Ggw 94: 364-366.
36. Santen RJ, Allred DC, Ardoin SP, Archer DF, Boyd N, et al. (2010) Postmenopausal Hormone Therapy: An Endocrine Society Scientific Statement. J Clin Endocrinol Metab 95: s1-s66.
37. Ahmed SB, Culleton BF, Tonelli M, Klarenbach SW, Macrae JM, et al. (2008) Oral estrogen therapy in postmenopausal women is associated with loss of kidney function. Kidney Int 74: 370-376.
38. Meng X, Dai X, Liao TD, D'Ambrosio M, Wang F, et al. (2011) Dose-dependent toxic effects of high-dose estrogen on renal and cardiac injury in surgically postmenopausal mice. Life Sci 88: 178-186.
39. Schopick EL, Fisher ND, Lin J, Forman JP, Curhan GC, (2009) Post-menopausal hormone use and albuminuria. Nephrol Dial Transplant 24: 3739-3744.
40. Mundel P, Reiser J, Zuniga Mejia BA, Pavenstadt H, Davidson GR, et al. (1997) Rearrangements of the cytoskeleton and cell contacts induce process formation during differentiation of conditionally immortalized mouse podocyte cell lines. Exp Cell Res 236: 248-258.
41. Aulmann S, Adler N, Rom J, Helmchen B, Schirmacher P, et al. (2006) c-myc amplifications in primary breast carcinomas and their local recurrences. J Clin Pathol 59: 424-428.
42. Distelmaier F, Koopman WJ, Testa ER, de Jong AS, Swarts HG, et al. (2008) Life cell quantification of mitochondrial membrane potential at the single organelle level. Cytometry A 73: 129-138.
43. Dupont S, Krust A, Gansmuller A, Dierich A, Chambon P, et al. (2000) Effect of single and compound knockouts of estrogen receptors alpha (ERalpha) and beta (ERbeta) on mouse reproductive phenotypes. Development 127: 4277-4291.
44. Irzyniec T, Mall G, Greber D, Ritz E, (1992) Beneficial effect of nifedipine and moxonidine on glomerulosclerosis in spontaneously hypertensive rats. A micromorphometric study. Am J Hypertens 5: 437-443.
45. El Nahas AM, Bassett AH, Cope GH, Le Carpentier JE, (1991) Role of growth hormone in the development of experimental renal scarring. Kidney Int 40: 29-34.
46. Amann K, Nichols C, Tornig J, Schwarz U, Zeier M, et al. (1996) Effect of ramipril, nifedipine, and moxonidine on glomerular morphology and podocyte structure in experimental renal failure. Nephrol Dial Transplant 11: 1003-1011.
47. Guo G, Morrissey J, McCracken R, Tolley T, Liapis H, et al. (2001) Contributions of angiotensin II and tumor necrosis factor-alpha to the development of renal fibrosis. Am J Physiol Renal Physiol 280: F777-785.
48. Amann K, Koch A, Hofstetter J, Gross ML, Haas C, et al. (2001) Glomerulosclerosis and progression: effect of subantihypertensive doses of alpha and beta blockers. Kidney Int 60: 1309-1323.
49. Schwarz U, Amann K, Orth SR, Simonaviciene A, Wessels S, et al. (1998) Effect of 1,25 (OH)2 vitamin D3 on glomerulosclerosis in subtotally nephrectomized rats. Kidney Int 53: 1696-1705.